在非手术患者群体中使用非标签前胺复合物缩物 (4F-PCC) 的利用和安全性
Katherine Sandquist1, Kevin Kaucher, Joshua Newell
1Department of Pharmacy, University of New Mexico Hospital, Albuquerque, New Mexico, USA.
概括
这项研究研究了四因子原胺复合度 (4F-PCC) 在非血液稀释剂患者的使用情况. 虽然它在停止出血方面取得了一些成功,但观察到高血制品使用率和死亡率.
科学领域:
- 医学 医学 医学 医学 医学
- 药理学 药理学是指药理学的学科.
- 关键的护理关键的护理
背景情况:
- 四因子原复合缩物 (4F-PCC) 用于治疗出血,但其在非抗凝血患者的非标签用途缺乏广泛的数据.
- 了解4F-PCC在这种特定人群中的安全性和有效性对于临床实践至关重要.
研究的目的:
- 评估4F-PCC在非抗凝血,非手术患者中的利用和安全性.
- 在4F-PCC注射后,评估静血效果,血液制品的使用,血栓事件,死亡率和住院.
主要方法:
- 对接受4F-PCC治疗的成年患者 (≥18岁) 进行了回顾性,单中心的图表审查,用于非手术指示.
- 纳入标准:非抗凝血状态和2017年1月至2022年9月期间至少一次4F-PCC剂量.
- 评估结果:静血疗效,血液制品的使用,30天的血栓事件,住院死亡率和住院时间.
主要成果:
- 59名患者符合标准:10名患者患有肝病,34名患者患有内出血,15名患者患有其他症状.
- 85%的非ICH患者实现了血静;64%的ICH患者在重复CT时没有扩张.
- 4F-PCC后使用血液制品的高率 (72.9%),急性血栓栓塞事件 (10.2%) 和住院死亡率 (55.9%).
结论:
- 非标签的4F-PCC使用在非抗凝血患者中很常见,尽管指导范围有限.
- 服用4F-PCC与频繁使用血液制品,高死亡率和血栓栓塞并发症有关.
- 需要进一步的研究来验证4F-PCC在这个患者群体中的使用.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
692
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
692
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
176
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
176


